In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 121 to 130 of 342

TitleTypeExpected publication date
Ganaxolone for adjunctive treatment of epilepsy associated with tuberous sclerosis complex with CDKL5 deficiency disorder [TSID12126]Technology appraisal guidanceTBC
Gefurulimab for treating antibody-positive generalised myasthenia gravis [TSID12256]Technology appraisal guidanceTBC
Giredestrant with everolimus for treating oestrogen-receptor positive HER2-negative advanced breast cancer after cyclin-dependent kinase 4 and 6 inhibitor and endocrine treatment ID6576Technology appraisal guidanceTBC
Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID5072]Technology appraisal guidanceTBC
Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A ID6312Technology appraisal guidanceTBC
Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [ID6323]Technology appraisal guidanceTBC
Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis [ID6487]Technology appraisal guidance
Govorestat for treating classic galactosemia in people 2 to 65 years [TSID12071]Technology appraisal guidanceTBC
Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]Technology appraisal guidance
Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All